Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shared REMS Systems Show Challenges Of Standardization – Could PDUFA V Help?

Executive Summary

Hurdles to developing multi-sponsor programs include disagreements on design, decision-making and cost-sharing. PDUFA V initiatives on standardizing and integrating REMS could give FDA a means for providing more formal guidance or rulemaking on developing shared systems, as some in industry have requested.


Related Content

Should Patents On REMS Distribution Restrictions Be Banned?
FDA Polled Review Staff On Avandia REMS Changes
FDA Replaces Avandia REMS Distribution Restrictions With Prescriber Training
REMS Modification Guidance Coming As FDA Rejects Petition For Shared REMS Rules
A Look At The First Six Shared REMS
Avandia Committee Gives Split Vote To Drug, But FDA Clear Winner
Everything REMS Under The Sun: FDA Lays Out Ambitious PDUFA V Meeting Agenda
Opioid Prescriber Knowledge Assessment Due Year After Patient Assessment
PDUFA Commitment Letter Formalizes REMS Standardization Schedule
Record-Setting REMS: FDA’s Classwide Opioid Program Will Be “Massive”


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts